Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review

dc.contributor.authorPitak-Arnnop P.
dc.contributor.authorNgamskulrungroj P.
dc.contributor.authorMahanonda N.
dc.contributor.authorAuychai P.
dc.contributor.authorFrech B.
dc.contributor.authorShavlokhova V.
dc.contributor.authorStoll C.
dc.contributor.correspondencePitak-Arnnop P.
dc.contributor.otherMahidol University
dc.date.accessioned2024-04-04T18:20:32Z
dc.date.available2024-04-04T18:20:32Z
dc.date.issued2024-03-01
dc.description.abstractWhile the World Health Organization (WHO) has de-escalated coronavirus disease 2019 (COVID-19) from a global health emergency, ongoing discussions persist as new viral variants. This article aimed to consolidate German recommendations and international research to offer health care providers (HCPs) a comprehensive guide on COVID-19 boosters in 2024. The review outlines key recommendations from the German Robert Koch Institute. HCPs should receive COVID-19 boosters at least 12 months after their last vaccination or COVID-19 infection, contingent on the prevalent viral variant(s) in the region. However, excessive doses and/or frequent boosters, especially with mRNA vaccines, may lead to immune imprinting, T-cell exhaustion, and immunoglobulin (Ig) switching. Notably, this review highlights the significance of Ig, particularly IgA and IgG subclasses, in influencing infection risk and disease progression. Furthermore, it explores the implications of mRNA vaccine technology and potential adverse effects related to excessive dosing. In conclusion, this article provides a comprehensive analysis of COVID-19 vaccine boosters for HCPs, synthesising current recommendations, scientific debates, and considerations for optimising protection against SARS-CoV-2 in the evolving landscape of the post-pandemic era.
dc.identifier.citationMedicina (Lithuania) Vol.60 No.3 (2024)
dc.identifier.doi10.3390/medicina60030385
dc.identifier.eissn16489144
dc.identifier.issn1010660X
dc.identifier.scopus2-s2.0-85188943141
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/97860
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleCurrent German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review
dc.typeReview
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85188943141&origin=inward
oaire.citation.issue3
oaire.citation.titleMedicina (Lithuania)
oaire.citation.volume60
oairecerif.author.affiliationSiriraj Hospital
oairecerif.author.affiliationChulabhorn Royal Academy
oairecerif.author.affiliationUniversitätsklinikum Gießen und Marburg, Standort Marburg
oairecerif.author.affiliationThai Association of Pediatric Dentistry
oairecerif.author.affiliationGLG Werner Forßmann Hospital Eberswalde—Academic Teaching Hospital of Charité Medical University Berlin
oairecerif.author.affiliationUniversity Hospital Ruppin-Brandenburg
oairecerif.author.affiliationRoyal College of Dentists of Thailand
oairecerif.author.affiliationPrivate Practice

Files

Collections